FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of November 2019
Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
EXHIBIT
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||
Date: November 21, 2019 | By: | /s/ Takashi Okubo | ||||
Takashi Okubo Global Head of Investor Relations |
Takeda Information
Takeda to Host R&D Day & Plasma-Derived Therapies Day in Tokyo, Japan
Osaka, JAPAN, November 21, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) will host a combined R&D Day and Plasma-Derived Therapies (PDT) Day on November 21, 2019 in Tokyo, Japan, from 11:00 a.m. to 5:00 p.m. JST, for investors and analysts. The Japanese and English language versions of the R&D Day presentation and PDT Day presentation, which include contents that were presented in New York on November 14 and in Covington on November 15, respectively, are attached.
Also, a webcast of the event will be made available on the FY19 Special IR Events section at https://www.takeda.com/investors/reports/quarterly-announcements/quarterly-announcements-2019/.
# # #
4